GlassScriptPhysician profile
Lloyd Javier
NPI 1558503680
$3,284.91
in general payments reported to CMS, 2019-2025
32 companies · $749 in 2025
The $749 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $170 · 2021: $202 · 2022: $217 · 2023: $672 · 2024: $833 · 2025: $749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,254.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $643.78 | 2021-2025 | |
| Glaxosmithkline, LLC. | $494.56 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $494.45 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $204.29 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $175.79 | 2019-2025 | |
| Amgen INC. | $170.67 | 2022-2025 | Evenity, Prolia, Otezla |
| Astrazeneca Pharmaceuticals LP | $161.84 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.01 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $121.80 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $98.23 | 2022-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.71 | 2022-2025 | Caplyta |
| Allergan, INC. | $85.65 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $45.78 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.13 | 2020-2023 | Trintellix |
| Corium, LLC | $32.80 | 2023-2024 | Azstarys |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $21.73 | 2024 | Auvelity |
| Shield Therapeutics INC | $21.55 | 2023 | Accrufer |
| Sumitomo Pharma America, INC. | $20.04 | 2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.86 | 2019 | |
| Antares Pharma, INC. | $19.66 | 2025 | Xyosted |
| Janssen Pharmaceuticals, INC | $18.02 | 2020 | |
| Novartis Pharmaceuticals Corporation | $17.58 | 2023 | |
| Tris Pharma INC | $17.19 | 2024 | Dyanavel Xr |
| Merck Sharp & Dohme LLC | $16.60 | 2019 | |
| Abbott Laboratories | $15.91 | 2025 | Freestyle Libre 3 |
| Ironshore Pharmaceuticals INC. | $15.21 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.60 | 2024 | |
| Idorsia Pharmaceuticals US INC | $14.56 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $13.76 | 2024 | Voquezna |
| Coopersurgical, INC. | $13.16 | 2023 | Paragard T 380a |
| Ultragenyx Pharmaceutical INC. | $12.98 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lloyd Javier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.